Update shared on15 Aug 2025
With consensus forecasts for both revenue growth and net profit margin remaining steady, analysts have left their fair value estimate for Allurion Technologies unchanged at $8.38.
What's in the News
- Allurion Technologies announced a strategic Canadian distribution partnership with Minogue Medical Inc., leveraging Minogue's national network of obesity care providers to expand access to Allurion's metabolically healthy weight loss program.
- The partnership is expected to boost provider adoption of a combined approach using the Allurion Program and GLP-1 therapy, aiming to enhance both short-term and long-term obesity management results.
- Allurion submitted the fourth and final module of its Pre-Market Approval (PMA) application to the FDA for its intragastric balloon, supported by the AUDACITY Study meeting both co-primary endpoints.
- The AUDACITY Study demonstrated significantly greater total body weight loss with the Allurion Balloon compared to controls at 48 weeks, with a 2.69% super-superiority margin.
- The FDA pivotal trial is notable as the first intragastric balloon study to report primary outcomes beyond 9 months, strengthening the clinical evidence for Allurion's device.
Valuation Changes
Summary of Valuation Changes for Allurion Technologies
- The Consensus Analyst Price Target remained effectively unchanged, at $8.38.
- The Consensus Revenue Growth forecasts for Allurion Technologies remained effectively unchanged, at -0.7% per annum.
- The Net Profit Margin for Allurion Technologies remained effectively unchanged, at 11.68%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.